This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
All Wales Medicines Strategy Group (AWMSG). Ropinirole prolonged-release (Requip XL®) for the treatment of idiopathic Parkinson's disease. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1409. 2009
Ropinirole prolonged-release (Requip XL®) is recommended for use within NHS Wales for the treatment of idiopathic Parkinson's disease in patients already taking ropinirole immediate-release tablets (Requip®) and in whom adequate symptomatic control has been established.
Substitution of ropinirole prolonged-release tablets for ropinirole immediate-release may be used as:
(i) Monotherapy, alone (without levodopa) in idiopathic Parkinson's disease
(ii) Adjunctive therapy in addition to levodopa to control 'on-off' fluctuations which might permit a reduction in the total daily dose of levodopa.
In order to limit errors, prolonged-release ropinirole should be prescribed by brand as Requip XL®.
AWMSG is of the opinion that prolonged-release ropinirole (Requip XL®) may be suitable for shared care in accordance with appropriate guidance.
Subject indexing assigned by CRD
Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agonists; Indoles; Parkinson Diseases
Country of organisation
An English language summary is available.
Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Date abstract record published